Doing Less Can Be Doing More for Healthcare – the Biggest Takeaway From ASCO 2018
Health Populi
JUNE 5, 2018
” A genetic test that costs $3,000 helps to identify women who could benefit from avoiding chemo. The test is called the Oncotype DX Breast Recurrence Score. We are de-escalating toxic therapy.” This would amount to about 60,000 women a year in the U.S. Thanks to the U.S.
89 
Let's personalize your content